Clinical Trial Update: A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating lanreotide as maintenance therapy in non-resectable duodeno-pancreatic neuroendocrine tumors was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodeno-pancreatic Neuroendocrine Tumors
• Neuroendocrine Tumors

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-10-04